TENOFOVIR DISOPROXIL fumarate 300mg, eq. 245mg base, tab.
STD
DORATENO3T-
Valid Article
Account code:
60000
HS Code:
300490
Last Updated on:
17/05/2024, 22:00:16
Former
Code(s):
DORAMISC426 DORAZBD0426
6.4.2.1 - Nucleoside/Nucleotide reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
6.4.4.1.1 - Nucleoside/Nucleotide reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AF07
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
TENOFOVIR (TDF)
Therapeutic Action
Antiretroviral, nucleotide reverse transcriptase inhibitor (NRTI)
Indications
Chronic hepatitis B virus (HBV) infection in adults and children from 2 years of age.
No longer recommended for HIV treatment: replaced by FDCs.
Instructions for use
300 mg tenofovir fumarate is equivalent to 245 mg tenofovir base.
Entecavir (ETV), another antiviral NRTI, is also recommended as first-line treatment in chronic hepatitis B virus infection.
TDF + lamivudine (3TC) or TDF + emtricitabine (FTC) are recommended as alternative regimens (where TDF monotherapy is not available).
For HIV treatment, use fixed-dose combinations containing tenofovir.
Storage
Below 25ºC